循环肿瘤DNA分析定义尤文肉瘤风险分层:儿童肿瘤学组与LEOPARD研究
该研究前瞻性验证了治疗前循环肿瘤DNA(ctDNA)负荷在尤文肉瘤中的预后价值,并整合ctDNA与临床分子特征构建低、中、高危风险组。局部病变和转移病变患者中,高基线ctDNA均与更差结局相关,且特定组合可识别无事件低危组。
要点
- 治疗前高ctDNA负荷与局部和转移性尤文肉瘤的不良结局独立相关。
- 局部病变、低ctDNA、小肿瘤且基因组学良好者无事件,构成新低危组。
- 转移病变中仅肺转移、低ctDNA且基因组学良好者属中危组。
核心结论
- 治疗前ctDNA负荷是尤文肉瘤的预后因素,整合ctDNA与临床分子特征可区分低、中、高危患者。
研究设计与样本
- 前瞻性研究者发起的生物学研究(LEOPARD)嵌入北美前线转移性研究AEWS1221,纳入新诊断尤文肉瘤患者。
- 140例局部病变和255例转移病变患者提供可评估的治疗前血样进行ctDNA分析,采用超低深度全基因组测序和杂交捕获面板测序。
- 部分患者进行连续ctDNA测序,分析ctDNA负荷与继发基因组事件、临床特征及结局的关联。
主要发现
- 高基线ctDNA与分期、肿瘤大小、原发部位、不确定肺结节及转移模式相关。
- 转移病变患者中,TP53变异和/或治疗中持续ctDNA阳性者结局极差。
- 局部病变、低ctDNA、小肿瘤且基因组学良好者无事件,构成新低危组。
关键数值与推荐
- 低危组定义:局部病变、低ctDNA、小肿瘤、有利基因组学,无事件。
- 中危组定义(转移病变):仅肺转移、低ctDNA、有利基因组学。
- 高危组:转移病变伴TP53变异和/或治疗中持续ctDNA阳性,结局极差。
临床怎么用
- 治疗前ctDNA检测可用于尤文肉瘤预后分层,辅助识别低危、中危和高危患者。
- 整合ctDNA负荷与临床分子特征(如TP53状态、肿瘤大小、转移模式)指导风险分组。
- 治疗中连续ctDNA监测可能有助于识别高危患者,尤其是转移病变中持续阳性者。
局限性
- 连续ctDNA测序仅在每项研究的部分患者中进行,非全部人群。
- 风险分组基于探索性分析,需进一步外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Identification of discrete risk groups remains a high priority for patients with Ewing sarcoma (EWS). We sought to prospectively validate circulating tumor DNA (ctDNA) as a prognostic factor and develop clinical-molecular risk groups. METHODS: We conducted a prospective investigator-initiated biology study for patients with localized EWS (LEOPARD) and embedded ctDNA analysis into the North American frontline metastatic study AEWS1221. Eligible patients were younger than 50 years with newly diagnosed EWS. All patients provided a baseline blood sample for analysis, which was subjected to ultralow-pass whole-genome sequencing and hybrid capture panel sequencing for ctDNA quantification, fusion detection, and characterization of STAG2 and TP53 alterations. Serial ctDNA sequencing was conducted on a subset of patients in each study. We tested for associations between ctDNA burden and secondary genomic events, and clinical features and outcomes. RESULTS: One hundred forty patients with localized disease and 255 with metastatic disease provided evaluable pretreatment samples for ctDNA analysis. Elevated baseline ctDNA was associated with stage, tumor size, primary site, indeterminate pulmonary nodules, and metastatic pattern. Elevated pretreatment ctDNA burden was associated with inferior outcomes in patients with localized (n = 140, hazard ratio [HR] = 2.36, P = .032) and metastatic disease (n = 255, HR = 2.15, P = .001). Patients with metastatic disease and TP53 variants and/or persistent on-therapy ctDNA had dismal outcomes. Patients with localized disease, low ctDNA, small tumors, and favorable genomics had no events and constitute a novel low-risk group. Among patients with metastatic disease, those with lung-only disease, low ctDNA, and favorable genomics represent an intermediate-risk group. CONCLUSION: This study prospectively validates pretreatment ctDNA burden as prognostic in EWS. Risk groups that integrate ctDNA burden with clinical-molecular features differentiate patients with low-, intermediate-, and high-risk disease.
引用
- Shulman DS, Klega K, Chen N, et al. Circulating Tumor DNA Profiling Defines Risk Classification in Patients With Ewing Sarcoma: A Report From the Children's Oncology Group and the LEOPARD Study. J Clin Oncol. 2026. PMID: 42743455. doi:10.1200/JCO-26-00285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。